Clinical Trials Browser

Completed × INDUSTRY × Carcinoma in Situ × Clear all

Carcinoma in Situ, Dysplastic Nevus Syndrome, Nevus

NCT05085977 2025-01-27

ADVANCED-1

Phase 1 Completed

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05085990 2025-01-27

ADVANCED-1

Phase 1 Completed

10 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04387461 2024-09-25

CORE-001

Phase 2 Completed

35 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT02486640 2023-07-24

BETAPREDICT

Completed

162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT04312737 2023-01-06

EU-VALHUDES

Completed

600 enrolled

Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type

NCT03134573 2019-03-26

PROmyBETAapp

Completed

96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

NCT01316874 2015-06-12

Bladder Cancer

Phase 2/3 Completed

90 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Phase 2 Completed

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00141531 2012-06-14

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Phase 2 Completed

53 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

Skin Fluorescent Imaging (SFI) System in Patients With Nevi

ADVANCED-1

ADVANCED-1

CORE-001

BETAPREDICT

EU-VALHUDES

PROmyBETAapp

Bladder Cancer

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer